 | |
Native name | 小野薬品工業 |
|---|---|
| Company type | Public (K.K) |
| TYO: 4528 | |
| ISIN | JP3197600004 |
| Industry | Pharmaceuticals |
| Founded | 1717 as Fushimiya Ichibei apothecary |
| Founder | Ichibei Ono I |
| Headquarters | Chuo-ku, Osaka, 541-8564 , Japan |
Area served | Worldwide |
Key people | Gyo Sagara (President and CEO) |
| Products |
|
| Revenue |  JPY 261.8 billion (FY 2017)
(US$ 2.4 billion) (FY 2017) |
 JPY 50.2 billion (FY 2017)
(US$ 474 million) (FY 2017) | |
Number of employees | 3,576 (consolidated, as of September 30, 2018) |
| Website | Official website |
| Footnotes / references [1][2][3] | |
Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka.,[4] and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.[5]
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.[6]
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.[7]
Nivolumab, the cancer drug based on the research of Prof.Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.[8]
